Advertisement
GNPX vs LONA
Which Stock Would AI Choose? Genprex, Inc. (GNPX) vs. LeonaBio, Inc. (LONA) Stock Comparison
Key Takeaways
- Both GNPX and LONA are clinical-stage biotechnology companies, but they occupy very different positions within the sector's risk spectrum.
- GNPX (Genprex) is a deeply de-risked micro-cap gene therapy developer, while LONA (LeonaBio) holds a late-stage, Phase 3 oncology asset backed by a sizable private financing.
- Tickeron AI Verdict: based on trend consistency, balance-sheet strength, and nearer-term catalysts, the AI currently favors LONA over GNPX.
- Relative performance diverges sharply: GNPX has experienced severe multi-month declines, whereas LONA has attracted fresh analyst coverage and institutional capital.
- Get more context on these names by exploring GNPX Major News and GNPX Today's Price Move, or LONA Major News and LONA Today's Price Move.
- For data-driven strategies across thousands of tickers, explore Trending AI Robots.
Introduction
Investors scanning the biotechnology sector often weigh high-risk, early-stage science against better-funded, later-stage programs. This stock comparison examines two names on opposite ends of that trade-off: GNPX (Genprex, Inc.), a clinical-stage gene therapy company, and LONA (LeonaBio, Inc.), a clinical-stage biopharmaceutical firm focused on oncology and neurodegenerative disease. Both generate little to no revenue and depend on clinical milestones and financing to advance, making them relevant primarily to investors who understand binary, catalyst-driven risk. Understanding their contrasting market positioning, cash resources, and momentum helps clarify how these two speculative names compare in the current environment.
GNPX Overview and Recent Performance
GNPX is Genprex, Inc., a clinical-stage gene therapy company headquartered in Austin, Texas, developing therapies for cancer and diabetes. Its lead candidate, Reqorsa (quaratusugene ozeplasmid) gene therapy, targets non-small cell lung cancer and small cell lung cancer, while GPX-002 is an earlier-stage diabetes program. Recent weeks have brought a steady stream of intellectual-property and scientific updates, including patent grants in Japan and the European Union, a Canadian notice of allowance, and an Israeli patent grant for Reqorsa combinations with PD-1/PD-L1 antibodies. The company has also announced biomarker research collaborations and data presentations at major oncology meetings.
Despite this flow of news, GNPX has experienced sustained relative performance weakness, reflecting a low market capitalization, frequent share-count adjustments, and recurring capital needs typical of micro-cap biotechnology. These factors have contributed to elevated volatility and a sharp, longer-term downtrend that outweighs the periodic, news-driven spikes.
LONA Overview and Recent Performance
LONA is LeonaBio, Inc., formerly Athira Pharma, which adopted its new name and ticker in January 2026. The rebranding followed a transformative license of lasofoxifene, a selective estrogen receptor modulator (SERM, a class of drug that acts on estrogen receptors) being studied in the Phase 3 ELAINE-3 trial for estrogen receptor-positive, ESR1-mutated metastatic breast cancer. The company also retains ATH-1105, an oral small molecule in development for amyotrophic lateral sclerosis (ALS).
The lasofoxifene transaction was accompanied by a $90 million private placement, with warrants that could provide up to roughly $146 million more if fully exercised. This financing attracted institutional investors and helped establish a longer cash runway. In recent weeks, LONA has gained sell-side attention, including an Overweight initiation from Piper Sandler, and its average analyst price target has implied notable upside from recent trading levels. This combination of a late-stage catalyst, fresh capital, and growing coverage has supported comparatively steadier sentiment than its peer.
Trending AI Robots
Tickeron's Trending AI Robots page curates the strongest performers from a broad marketplace of AI trading bots that collectively monitor thousands of different tickers. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific sets of securities they follow, so only those best suited to current market conditions earn a place in the trending selection. Rather than applying a single strategy to every name, each bot adapts its approach to the asset it tracks. For investors who want a systematic, data-driven complement to their own analysis of names like GNPX and LONA, reviewing the curated Trending AI Robots list is a practical starting point.
Head-to-Head Comparison
The most visible contrast between these two companies is stage of development and financial scale. LONA owns a Phase 3 oncology candidate with a defined data readout timeline and recently secured substantial institutional funding, giving it greater runway and clearer catalysts. GNPX, by contrast, is advancing earlier-stage gene therapy programs against a much smaller balance sheet, exposing shareholders to more frequent dilution risk and higher sensitivity to single data or regulatory events.
Risk profiles also differ. Both are pre-revenue and carry binary clinical risk, but GNPX's micro-cap structure amplifies volatility and reduces institutional participation, while LONA benefits from a more diversified pipeline spanning oncology and neurology. In terms of market sentiment, LONA has enjoyed a favorable repricing tied to its strategic pivot and analyst endorsements, whereas GNPX's positive news flow has not yet translated into durable relative momentum.
Tickeron AI Verdict
Weighing observable factors such as trend consistency, stability, capital resources, and the proximity of value-driving catalysts, Tickeron's AI currently expresses a probabilistic preference for LONA over GNPX. The reasoning centers on LONA's larger capital base, a late-stage Phase 3 program, and comparatively constructive analyst positioning, which together suggest a steadier risk-reward profile. This is not a definitive forecast; biotechnology outcomes are inherently uncertain, and either name could re-rate on future clinical or financing developments. The verdict simply reflects which of the two the AI would favor in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNPX is a Hold and LONA is a Hold.
GNPX saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for GNPX moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 32 similar instances where the indicator exited the overbought zone. In 32 of the 32 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for GNPX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GNPX's RSI Indicator exited the oversold zone, 36 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on GNPX as a result. In 60 of 71 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
Following a +11.44% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in 150 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
GNPX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.115) is normal, around the industry mean (3.498). P/E Ratio (0.060) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. GNPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
LONA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 10, 2026
LONA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 45 of 48 cases where LONA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for LONA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where LONA advanced for three days, in 214 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LONA as a result. In 74 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for LONA turned negative on November 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LONA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for LONA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.238) is normal, around the industry mean (3.498). P/E Ratio (-0.192) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. LONA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LONA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
GNPX | LONA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 55 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 49 Fair valued | 60 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 93 | 65 | |
P/E GROWTH RATING 1..100 | 84 | 12 | |
SEASONALITY SCORE 1..100 | 29 | 42 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GNPX's Valuation (49) in the Pharmaceuticals Major industry is in the same range as LONA (60) in the null industry. This means that GNPX’s stock grew similarly to LONA’s over the last 12 months.
GNPX's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as LONA (100) in the null industry. This means that GNPX’s stock grew similarly to LONA’s over the last 12 months.
GNPX's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as LONA (100) in the null industry. This means that GNPX’s stock grew similarly to LONA’s over the last 12 months.
LONA's Price Growth Rating (65) in the null industry is in the same range as GNPX (93) in the Pharmaceuticals Major industry. This means that LONA’s stock grew similarly to GNPX’s over the last 12 months.
LONA's P/E Growth Rating (12) in the null industry is significantly better than the same rating for GNPX (84) in the Pharmaceuticals Major industry. This means that LONA’s stock grew significantly faster than GNPX’s over the last 12 months.
| GNPX | LONA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 83% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| MACD ODDS (%) | N/A | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Advances ODDS (%) | 13 days ago 76% | 3 days ago 83% |
| Declines ODDS (%) | 3 days ago 90% | 7 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GNPX’s FA Score shows that 0 FA rating(s) are green while LONA’s FA Score has 1 green FA rating(s).
- GNPX’s FA Score: 0 green, 5 red.
- LONA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GNPX’s TA Score shows that 4 TA indicator(s) are bullish while LONA’s TA Score has 4 bullish TA indicator(s).
- GNPX’s TA Score: 4 bullish, 3 bearish.
- LONA’s TA Score: 4 bullish, 4 bearish.
Price Growth
GNPX (@Biotechnology) experienced а -9.52% price change this week, while LONA (@Biotechnology) price change was -15.72% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
GNPX is expected to report earnings on Nov 13, 2026.
LONA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LONA and
Correlation & Price change
A.I.dvisor indicates that over the last year, LONA has been closely correlated with CANF. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if LONA jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To LONA | 1D Price Change % | ||
|---|---|---|---|---|
| LONA | 100% | -10.07% | ||
| CANF - LONA | 77% Closely correlated | -1.19% | ||
| ICU - LONA | 76% Closely correlated | -3.06% | ||
| GNPX - LONA | 62% Loosely correlated | +1.46% | ||
| MLEC - LONA | 58% Loosely correlated | N/A | ||
| CNTN - LONA | 40% Loosely correlated | -3.63% | ||
More | ||||